Advertisement

Challenges and Promises of Pediatric Psychopharmacology

  • Lisa L. Giles
    Correspondence
    Address correspondence to Lisa L. Giles, MD, Department of Psychiatry and Behavioral Health, Primary Children's Hospital, 100 N Mario Capecchi Dr, Salt Lake City, UT 84113.
    Affiliations
    Departments of Pediatrics and Psychiatry, University of Utah School of Medicine and Department of Psychiatry and Behavioral Health, Primary Children's Hospital, Salt Lake City, Utah
    Search for articles by this author
  • D. Richard Martini
    Affiliations
    Departments of Pediatrics and Psychiatry, University of Utah School of Medicine and Department of Psychiatry and Behavioral Health, Primary Children's Hospital, Salt Lake City, Utah
    Search for articles by this author
Published:April 05, 2016DOI:https://doi.org/10.1016/j.acap.2016.03.011

      Abstract

      Most prescriptions for psychotropic medications are written by primary care physicians, yet pediatricians, many of whom are teaching residents and medical students about pediatric psychopharmacology, often feel inadequately trained to treat mental health concerns. Over the past several decades, the number, size, and quality of psychopharmacologic studies in youth has greatly increased. Here we review the current evidence for efficacy and safety of each of the major pharmacologic drug classes in youth (psychostimulants, antidepressants, mood stabilizers, and antipsychotics). Psychostimulants have a robust body of literature supporting their evidence as first-line treatment for attention-deficit/hyperactivity disorder. Selective serotonin reuptake inhibitors (SSRIs) have documented efficacy for pediatric depression and multiple different anxiety disorders with childhood onset. Combining cognitive-behavioral therapy with SSRI treatment enhances treatment benefit and minimizes adverse events of medication. Mood stabilizers, including lithium and anticonvulsant medications, have a less robust strength of evidence and come with more problematic side effects. However, they are increasingly prescribed to youth, often to treat irritability, mood lability, and aggression, along with treatment of bipolar disorder. Antipsychotics have long been a mainstay of treatment for childhood-onset schizophrenia, and in recent years, the evidence base for providing antipsychotics to youth with bipolar mania and autistic disorder has grown. Most concerning with antipsychotics are the metabolic side effects, which appear even more problematic in youth than adults. By better understanding the evidence-based psychopharmacologic interventions, academic pediatricians will be able to treat patients and prepare future pediatrician to address the growing mental health care needs of youth.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Academic Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Correll C.U.
        • Kratochvil C.J.
        • March J.S.
        Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics.
        J Clin Psychiatry. 2011; 72: 655-670
        • Rapoport J.L.
        Pediatric psychopharmacology: too much or too little?.
        World Psychiatry. 2013; 12: 118-123
        • Southammakosane C.
        • Schmitz K.
        Pediatric psychopharmacology for treatment of ADHD, depression, and anxiety.
        Pediatrics. 2015; 136: 351-359
        • Comer J.S.
        • Olfson M.
        • Mojtabai R.
        National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007.
        J Am Acad Child Adolesc Psychiatry. 2010; 49: 1001-1010
        • Merikangas K.R.
        • He J.P.
        • Rapoport J.
        • et al.
        Medication use in US youth with mental disorders.
        JAMA Pediatr. 2013; 167: 141-148
        • Rettew D.C.
        • Greenblatt J.
        • Kamon J.
        • et al.
        Antipsychotic medication prescribing in children enrolled in Medicaid.
        Pediatrics. 2015; 135: 658-665
        • Anderson L.E.
        • Chen M.L.
        • Perrin J.M.
        • et al.
        Outpatient visits and medication prescribing for US children with mental health conditions.
        Pediatrics. 2015; 136: e1178-e1185
        • Stein R.E.
        • Horwitz S.M.
        • Storfer-Isser A.
        • et al.
        Do pediatricians think they are responsible for identification and management of child mental health problems? Results of the AAP periodic survey.
        Ambul Pediatr. 2008; 8: 11-17
        • Pliszka S.
        • AACAP Work Group on Quality Issues
        Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 894-921
        • Wolraich M.
        • Brown L.
        • Brown R.T.
        • et al.
        • Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management
        ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.
        Pediatrics. 2011; 128: 1007-1022
      1. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children With ADHD.
        Arch Gen Psychiatry. 1999; 56: 1073-1086
        • Abikoff H.B.
        • Vitiello B.
        • Riddle M.A.
        • et al.
        Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
        J Child Adolesc Psychopharmacol. 2007; 17: 581-592
        • Molina B.S.
        • Hinshaw S.P.
        • Swanson J.M.
        • et al.
        The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.
        J Am Acad Child Adolesc Psychiatry. 2009; 48: 484-500
        • Greenhill L.
        • Kollins S.
        • Abikoff H.
        • et al.
        Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
        J Am Acad Child Adolesc Psychiatry. 2006; 45: 1284-1293
        • Faraone S.V.
        Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths.
        P T. 2009; 34: 678-694
        • Hirota T.
        • Schwartz S.
        • Correll C.U.
        Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.
        J Am Acad Child Adolesc Psychiatry. 2014; 53: 153-173
        • Hammerness P.G.
        • Perrin J.M.
        • Shelley-Abrahamson R.
        • et al.
        Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
        J Am Acad Child Adolesc Psychiatry. 2011; 50: 978-990
        • Hammerness P.G.
        • Karampahtsis C.
        • Babalola R.
        • et al.
        Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?.
        Exp Opin Drug Saf. 2015; 14: 543-551
        • Gould M.S.
        • Walsh B.T.
        • Munfakh J.L.
        • et al.
        Sudden death and use of stimulant medications in youths.
        Am J Psychiatry. 2009; 166: 992-1001
        • American Academy of Pediatrics/American Heart Association
        American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: 2008.
        J Dev Behav Pediatr. 2008; 29: 335
        • Hamilton R.M.
        • Rosenthal E.
        • Hulpke-Wette M.
        • et al.
        • European Network of Hyperkinetic Disorders
        Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting.
        Cardiol Young. 2012; 22: 63-70
        • Pliszka S.R.
        • Crismon M.L.
        • Hughes C.W.
        • et al.
        The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.
        J Am Acad Child Adolesc Psychiatry. 2006; 45: 642-657
        • Vitiello B.
        • Severe J.B.
        • Greenhill L.L.
        • et al.
        Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.
        J Am Acad Child Adolesc Psychiatry. 2001; 40: 188-196
        • Perou R.
        • Bitsko R.H.
        • Blumberg S.J.
        • et al.
        Mental health surveillance among children—United States, 2005–2011.
        MMWR Surveill Summ. 2013; 62: 1-35
        • Pediatric OCD Treatment Study (POTS) Team
        Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
        JAMA. 2004; 292: 1969-1976
        • Walkup J.T.
        • Albano A.M.
        • Piacentini J.
        • et al.
        Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.
        N Engl J Med. 2008; 359: 2753-2766
        • Compton S.N.
        • Walkup J.T.
        • Albano A.M.
        • et al.
        Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods.
        Child Adolesc Psychiatry Ment Health. 2010; 4: 1
        • March J.
        • Silva S.
        • Petrycki S.
        • et al.
        Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
        JAMA. 2004; 292: 807-820
        • March J.S.
        • Vitiello B.
        Clinical messages from the Treatment for Adolescents With Depression Study (TADS).
        Am J Psychiatry. 2009; 166: 1118-1123
        • Brent D.
        • Emslie G.
        • Clarke G.
        • et al.
        Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
        JAMA. 2008; 299: 901-913
        • March J.
        • Silva S.
        • Curry J.
        • et al.
        • Treatment for Adolescents With Depression Study (TADS) Team
        The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
        Am J Psychiatry. 2009; 166: 1141-1149
        • Bridge J.A.
        • Iyengar S.
        • Salary C.B.
        • et al.
        Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.
        JAMA. 2007; 297: 1683-1696
        • Strawn J.R.
        • Prakash A.
        • Zhang Q.
        • et al.
        A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.
        J Am Acad Child Adolesc Psychiatry. 2015; 54: 283-293
        • Strawn J.R.
        • Welge J.A.
        • Wehry A.M.
        • et al.
        Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis.
        Depress Anxiety. 2015; 32: 149-157
      2. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder.
        J Am Acad Child Adolesc Psychiatry. 2012; 51: 98-113
        • Robb A.S.
        • Cueva J.E.
        • Sporn J.
        • et al.
        Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial.
        J Child Adolesc Psychopharmacol. 2010; 20: 463-471
        • Hazell P.
        • Mirzaie M.
        Tricyclic drugs for depression in children and adolescents.
        Cochrane Database Syst Rev. 2013; 6: CD002317
        • Pittenger C.
        • Bloch M.H.
        Pharmacological treatment of obsessive-compulsive disorder.
        Psychiatr Clin North Am. 2014; 37: 375-391
        • Birmaher B.
        • Brent D.
        • AACAP Work Group on Quality Issues
        Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 1503-1526
        • Hammad T.A.
        • Laughren T.
        • Racoosin J.
        Suicidality in pediatric patients treated with antidepressant drugs.
        Arch Gen Psychiatry. 2006; 63: 332-339
        • Connolly S.D.
        • Bernstein G.A.
        • Work Group on Quality Issues
        Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 267-283
        • Hughes C.W.
        • Emslie G.J.
        • Crismon M.L.
        • et al.
        Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 667-686
        • Cheung A.H.
        • Zuckerbrot R.A.
        • Jensen P.S.
        • et al.
        Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management.
        Pediatrics. 2007; 120: e1313-e1326
        • McClellan J.
        • Kowatch R.
        • Findling R.L.
        Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 107-125
        • Findling R.L.
        • Kafantaris V.
        • Pavuluri M.
        • et al.
        Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder.
        J Child Adolesc Psychopharmacol. 2011; 21: 195-205
        • Findling R.L.
        • Robb A.
        • McNamara N.K.
        • et al.
        Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study.
        Pediatrics. 2015; 136: 885-894
        • Patel N.C.
        • DelBello M.P.
        • Bryan H.S.
        • et al.
        Open-label lithium for the treatment of adolescents with bipolar depression.
        J Am Acad Child Adolesc Psychiatry. 2006; 45: 289-297
        • Masi G.
        • Perugi G.
        • Millepiedi S.
        • et al.
        Pharmacological response in juvenile bipolar disorder subtypes: a naturalistic retrospective examination.
        Psychiatry Res. 2010; 177: 192-198
        • Liu H.Y.
        • Potter M.P.
        • Woodworth K.Y.
        • et al.
        Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis.
        J Am Acad Child Adolesc Psychiatry. 2011; 50: 749-762.e739
        • Geller B.
        • Luby J.L.
        • Joshi P.
        • et al.
        A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.
        Arch Gen Psychiatry. 2012; 69: 515-528
        • Walkup J.T.
        • Wagner K.D.
        • Miller L.
        • et al.
        Treatment of early-age mania: outcomes for partial and nonresponders to initial treatment.
        J Am Acad Child Adolesc Psychiatry. 2015; 54: 1008-1019
        • Salpekar J.A.
        • Joshi P.T.
        • Axelson D.A.
        • et al.
        Depression and suicidality outcomes in the treatment of early age mania study.
        J Am Acad Child Adolesc Psychiatry. 2015; 54: 999-1007.e1004
        • Correll C.U.
        • Sheridan E.M.
        • DelBello M.P.
        Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.
        Bipolar Disord. 2010; 12: 116-141
        • Ipser J.
        • Stein D.J.
        Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents.
        Psychopharmacology. 2007; 191: 127-140
        • Pringsheim T.
        • Hirsch L.
        • Gardner D.
        • et al.
        The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.
        Can J Psychiatry. 2015; 60: 52-61
        • Shon S.H.
        • Joo Y.
        • Lee J.S.
        • et al.
        Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review.
        J Child Adolesc Psychopharmacol. 2014; 24: 285-287
        • Findling R.L.
        • Chang K.
        • Robb A.
        • et al.
        Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study.
        J Am Acad Child Adolesc Psychiatry. 2015; 54: 1020-1031.e1023
        • Findling R.L.
        • Ginsberg L.D.
        The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode.
        Neuropsychiatr Dis Treat. 2014; 10: 1589-1597
        • Delbello M.P.
        • Findling R.L.
        • Kushner S.
        • et al.
        A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder.
        J Am Acad Child Adolesc Psychiatry. 2005; 44: 539-547
        • Wagner K.D.
        • Kowatch R.A.
        • Emslie G.J.
        • et al.
        A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents.
        Am J Psychiatry. 2006; 163: 1179-1186
        • Smarty S.
        • Findling R.L.
        Psychopharmacology of pediatric bipolar disorder: a review.
        Psychopharmacology. 2007; 191: 39-54
        • Kumra S.
        • Oberstar J.V.
        • Sikich L.
        • et al.
        Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.
        Schizophr Bull. 2008; 34: 60-71
        • McClellan J.
        • Stock S.
        American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia.
        J Am Acad Child Adolesc Psychiatry. 2013; 52: 976-990
        • Pappadopulos E.
        • Macintyre II, J.C.
        • Crismon M.L.
        • et al.
        Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.
        J Am Acad Child Adolesc Psychiatry. 2003; 42: 145-161
        • DelBello M.
        • Grcevich S.
        Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics.
        J Clin Psychiatry. 2004; 65: 12-19
        • Burcu M.
        • Zito J.M.
        • Ibe A.
        • et al.
        Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications.
        J Child Adolesc Psychopharmacol. 2014; 24: 112-119
        • Kumar A.
        • Datta S.S.
        • Wright S.D.
        • et al.
        Atypical antipsychotics for psychosis in adolescents.
        Cochrane Database Syst Rev. 2013; 10: CD009582
        • Sikich L.
        • Frazier J.A.
        • McClellan J.
        • et al.
        Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.
        Am J Psychiatry. 2008; 165: 1420-1431
        • Findling R.L.
        • Johnson J.L.
        • McClellan J.
        • et al.
        Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
        J Am Acad Child Adolesc Psychiatry. 2010; 49: 583-594
        • Findling R.L.
        • Landbloom R.L.
        • Szegedi A.
        • et al.
        Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder.
        J Am Acad Child Adolesc Psychiatry. 2015; 54: 1032-1041
        • Ji N.
        • Findling R.L.
        An update on pharmacotherapy for autism spectrum disorder in children and adolescents.
        Curr Opin Psychiatry. 2015; 28: 91-101
        • McDougle C.J.
        • Scahill L.
        • Aman M.G.
        • et al.
        Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.
        Am J Psychiatry. 2005; 162: 1142-1148
        • Aman M.G.
        • McDougle C.J.
        • Scahill L.
        • et al.
        Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
        J Am Acad Child Adolesc Psychiatry. 2009; 48: 1143-1154
        • Reyes M.
        • Buitelaar J.
        • Toren P.
        • et al.
        A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
        Am J Psychiatry. 2006; 163: 402-410
        • Aman M.G.
        • Bukstein O.G.
        • Gadow K.D.
        • et al.
        What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?.
        J Am Acad Child Adolesc Psychiatry. 2014; 53: 47-60.e41
        • Gadow K.D.
        • Arnold L.E.
        • Molina B.S.
        • et al.
        Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
        J Am Acad Child Adolesc Psychiatry. 2014; 53: 948-959.e941
        • Sallee F.R.
        • Kurlan R.
        • Goetz C.G.
        • et al.
        Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study.
        J Am Acad Child Adolesc Psychiatry. 2000; 39: 292-299
        • Dion Y.
        • Annable L.
        • Sandor P.
        • et al.
        Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial.
        J Clin Psychopharmacol. 2002; 22: 31-39
        • Yang C.S.
        • Huang H.
        • Zhang L.L.
        • et al.
        Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis.
        BMC Psychiatry. 2015; 15: 179
        • Budman C.L.
        The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.
        Drugs. 2014; 74: 1177-1193
        • Correll C.U.
        • Manu P.
        • Olshanskiy V.
        • et al.
        Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
        JAMA. 2009; 302: 1765-1773
        • Newcomer J.W.
        Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
        CNS Drugs. 2005; 19: 1-93
        • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity
        Consensus development conference on antipsychotic drugs and obesity and diabetes.
        Diabetes Care. 2004; 27: 596-601
        • Jensen K.G.
        • Juul K.
        • Fink-Jensen A.
        • et al.
        Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.
        J Am Acad Child Adolesc Psychiatry. 2015; 54: 25-36
        • Lane R.D.
        • Glazer W.M.
        • Hansen T.E.
        • et al.
        Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale.
        J Nerv Ment Dis. 1985; 173: 353-357
        • American Academy of Child and Adolescent Psychiatry
        Practice parameter on the use of psychotropic medication in children and adolescents.
        J Am Acad Child Adolesc Psychiatry. 2009; 48: 961-973